N-(3-Bromophenyl)-6-nitro-4-quinazolinamine(CAS: 169205-77-0)

N-(3-Bromophenyl)-6-nitro-4-quinazolinamine (CAS: 169205-77-0) must comply with GHS classification, including hazardous properties such as skin irritation and sensitization. For manufacturing and distribution, REACH regulations require registration, evaluation, and authorization. Additionally, FDA and EPA regulations may apply depending on its intended use, ensuring safe handling and disposal.

Yes, alternatives to N-(3-Bromophenyl)-6-nitro-4-quinazolinamine include other quinazolinamines or analogs with similar functionalities. Common alternative reagents include various amines and nitro compounds. Isomers and structurally similar compounds can also serve as viable substitutes, depending on the specific synthesis requirements.

Market trends for N-(3-Bromophenyl)-6-nitro-4-quinazolinamine (CAS: 169205-77-0) indicate growing interest in its applications, particularly in pharmaceuticals and materials science. Research is focusing on its potential as an intermediate in drug synthesis and as a functional compound in organic electronics. Demand is expected to rise with advancements in these fields, but market fluctuations may occur based on the discovery of new alternatives and regulatory changes.

Waste containing N-(3-Bromophenyl)-6-nitro-4-quinazolinamine (CAS: 169205-77-0) should be collected in appropriate containers and stored separately to prevent cross-contamination. Incineration or professional waste disposal services are recommended for safe disposal. Environmental protection precautions include using personal protective equipment and following local regulations to minimize environmental impact.